Latest news
Eli Lilly opens narrow early-access door to its experimental obesity drug - Benefits and Pensions MonitorBenefits and Pensions Monitor · Wed, 05 Aug 2026 11:46:23 GMTEli Lilly to Offer Experimental GLP-1 Retatrutide for Compassionate Use — Who Qualifies? - Everyday HealthEveryday Health · Wed, 05 Aug 2026 00:21:28 GMTAmgen second-quarter sales rise 9%, profit tops Street view - ReutersReuters · Tue, 04 Aug 2026 20:07:03 GMTEli Lilly will offer experimental obesity drug early to some patients. Who qualifies? - Houston ChronicleHouston Chronicle · Tue, 04 Aug 2026 19:37:30 GMTLilly Opens Pre-Approval Access to Its Next Obesity Drug - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 18:00:26 GMTEli Lilly Retatrutide Early Access Opens to a Small Group of Patients Before FDA Approval - NCHStatsNCHStats · Tue, 04 Aug 2026 10:48:43 GMTEli Lilly to offer limited early access to experimental weight-loss drug - medwatch.commedwatch.com · Tue, 04 Aug 2026 07:48:00 GMTEli Lilly to offer early access to next-gen obesity drug to some patients - ReutersReuters · Tue, 04 Aug 2026 01:23:52 GMT